Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

New pathogenic insights inform therapeutic target development for renal osteodystrophy.

Hruska KA, Mahjoub MR.

Kidney Int. 2019 Feb;95(2):261-263. doi: 10.1016/j.kint.2018.10.026.

PMID:
30665565
2.

Correction: Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis (doi: 10.1242/dmm.030130).

Olson PD, McLellan LK, Liu A, Briden KE, Tiemann KM, Daugherty AL, Hruska KA, Hunstad DA.

Dis Model Mech. 2018 Sep 13;11(9). pii: dmm036798. doi: 10.1242/dmm.036798. No abstract available.

3.

Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli.

Olson PD, McLellan LK, Hreha TN, Liu A, Briden KE, Hruska KA, Hunstad DA.

Kidney Int. 2018 Sep;94(3):502-513. doi: 10.1016/j.kint.2018.04.023. Epub 2018 Jul 3.

4.

Renal scar formation and kidney function following antibiotic-treated murine pyelonephritis.

Olson PD, McLellan LK, Liu A, Briden KE, Tiemann KM, Daugherty AL, Hruska KA, Hunstad DA.

Dis Model Mech. 2017 Nov 1;10(11):1371-1379. doi: 10.1242/dmm.030130. Epub 2017 Sep 7. Erratum in: Dis Model Mech. 2018 Sep 13;11(9):.

5.

The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.

Williams MJ, Sugatani T, Agapova OA, Fang Y, Gaut JP, Faugere MC, Malluche HH, Hruska KA.

Kidney Int. 2018 Jan;93(1):147-158. doi: 10.1016/j.kint.2017.06.016. Epub 2017 Aug 23.

6.

Crosstalk between kidney and bone - Bench to bedside.

Hruska KA, Lanske B, Moe OW.

Bone. 2017 Jul;100:1-3. doi: 10.1016/j.bone.2017.03.046. Epub 2017 Apr 11. No abstract available.

PMID:
28412470
7.

The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.

Hruska KA, Sugatani T, Agapova O, Fang Y.

Bone. 2017 Jul;100:80-86. doi: 10.1016/j.bone.2017.01.023. Epub 2017 Jan 22. Review.

8.

Bone Mineral Density and Progression of Subclinical Atherosclerosis in African-Americans With Type 2 Diabetes.

Wagenknecht LE, Divers J, Register TC, Russell GB, Bowden DW, Xu J, Langefeld CD, Lenchik L, Hruska KA, Carr JJ, Freedman BI.

J Clin Endocrinol Metab. 2016 Nov;101(11):4135-4141. Epub 2016 Aug 23.

9.

Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Sugatani T, Agapova OA, Fang Y, Berman AG, Wallace JM, Malluche HH, Faugere MC, Smith W, Sung V, Hruska KA.

Kidney Int. 2017 Jan;91(1):86-95. doi: 10.1016/j.kint.2016.07.039. Epub 2016 Sep 22.

10.

Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.

Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA.

Kidney Int. 2016 Jun;89(6):1231-43. doi: 10.1016/j.kint.2016.02.002. Epub 2016 Mar 11.

11.

Fibroblast growth factor-23 and chronic allograft injury in pediatric renal transplant recipients: a Midwest Pediatric Nephrology Consortium study.

Seifert ME, Ashoor IF, Chiang ML, Chishti AS, Dietzen DJ, Gipson DS, Janjua HS, Selewski DT, Hruska KA.

Pediatr Transplant. 2016 May;20(3):378-87. doi: 10.1111/petr.12682. Epub 2016 Feb 15.

12.

Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.

Freedman BI, Divers J, Russell GB, Palmer ND, Bowden DW, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Langefeld CD, Hruska KA, Register TC.

Am J Nephrol. 2015;42(6):391-401. doi: 10.1159/000443241. Epub 2015 Dec 23.

13.

Androgens Enhance Male Urinary Tract Infection Severity in a New Model.

Olson PD, Hruska KA, Hunstad DA.

J Am Soc Nephrol. 2016 Jun;27(6):1625-34. doi: 10.1681/ASN.2015030327. Epub 2015 Oct 8.

14.

The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.

Seifert ME, Hruska KA.

Transplantation. 2016 Mar;100(3):497-505. doi: 10.1097/TP.0000000000000903. Review.

15.

SIRT6 deficiency culminates in low-turnover osteopenia.

Sugatani T, Agapova O, Malluche HH, Hruska KA.

Bone. 2015 Dec;81:168-177. doi: 10.1016/j.bone.2015.07.018. Epub 2015 Jul 17.

16.

Pathophysiology of the chronic kidney disease-mineral bone disorder.

Hruska KA, Seifert M, Sugatani T.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):303-9. doi: 10.1097/MNH.0000000000000132. Review.

17.

Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.

Anyaegbu EI, Shaw AS, Hruska KA, Jain S.

Pediatr Nephrol. 2015 Jun;30(6):983-9. doi: 10.1007/s00467-014-3031-0. Epub 2014 Dec 23.

18.

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2014;39(5):392-9. doi: 10.1159/000362251. Epub 2014 May 6.

19.

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.

Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA.

J Am Soc Nephrol. 2014 Aug;25(8):1760-73. doi: 10.1681/ASN.2013080818. Epub 2014 Feb 27.

20.

Expression of DGCR8-dependent microRNAs is indispensable for osteoclastic development and bone-resorbing activity.

Sugatani T, Hildreth BE 3rd, Toribio RE, Malluche HH, Hruska KA.

J Cell Biochem. 2014 Jun;115(6):1043-7. doi: 10.1002/jcb.24759.

21.

Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study.

Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Dietzen DJ, Langefeld CD, Freedman BI.

J Clin Endocrinol Metab. 2014 Jan;99(1):315-21. doi: 10.1210/jc.2013-3168. Epub 2013 Dec 20.

22.

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2013;38(2):158-67. doi: 10.1159/000353569. Epub 2013 Aug 7.

23.

Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.

Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA.

Kidney Int. 2014 Jan;85(1):142-50. doi: 10.1038/ki.2013.271. Epub 2013 Jul 24.

24.

HDAC dependent transcriptional repression of Bmp-7 potentiates TGF-β mediated renal fibrosis in obstructive uropathy.

Manson SR, Song JB, Hruska KA, Austin PF.

J Urol. 2014 Jan;191(1):242-52. doi: 10.1016/j.juro.2013.06.110. Epub 2013 Jun 29.

25.

Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study.

Register TC, Divers J, Bowden DW, Carr JJ, Lenchik L, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Hruska KA, Langefeld CD, Freedman BI.

J Clin Endocrinol Metab. 2013 May;98(5):1916-22. doi: 10.1210/jc.2012-4126. Epub 2013 Mar 29.

26.

Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis.

Sugatani T, Hruska KA.

J Cell Biochem. 2013 Jun;114(6):1217-22. doi: 10.1002/jcb.24471.

27.

Admixture mapping of coronary artery calcified plaque in African Americans with type 2 diabetes mellitus.

Divers J, Palmer ND, Lu L, Register TC, Carr JJ, Hicks PJ, Hightower RC, Smith SC, Xu J, Cox AJ, Hruska KA, Bowden DW, Lewis CE, Heiss G, Province MA, Borecki IB, Kerr KF, Chen YD, Palmas W, Rotter JI, Wassel CL, Bertoni AG, Herrington DM, Wagenknecht LE, Langefeld CD, Freedman BI.

Circ Cardiovasc Genet. 2013 Feb;6(1):97-105. doi: 10.1161/CIRCGENETICS.112.964114. Epub 2012 Dec 11.

28.

Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study.

Murea M, Register TC, Divers J, Bowden DW, Carr JJ, Hightower CR, Xu J, Smith SC, Hruska KA, Langefeld CD, Freedman BI.

BMC Nephrol. 2012 Nov 14;13:148. doi: 10.1186/1471-2369-13-148.

29.

Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes.

Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Dietzen DJ, Langefeld CD, Freedman BI.

J Clin Endocrinol Metab. 2013 Jan;98(1):E60-5. doi: 10.1210/jc.2012-3038. Epub 2012 Nov 2.

30.

Endogenous BMP-7 is a critical molecular determinant of the reversibility of obstruction-induced renal injuries.

Manson SR, Niederhoff RA, Hruska KA, Austin PF.

Am J Physiol Renal Physiol. 2011 Dec;301(6):F1293-302. doi: 10.1152/ajprenal.00071.2011. Epub 2011 Aug 31.

31.

The BMP-7-Smad1/5/8 pathway promotes kidney repair after obstruction induced renal injury.

Manson SR, Niederhoff RA, Hruska KA, Austin PF.

J Urol. 2011 Jun;185(6 Suppl):2523-30. doi: 10.1016/j.juro.2011.01.034. Epub 2011 Apr 27.

32.

Relationships between calcified atherosclerotic plaque and bone mineral density in African Americans with type 2 diabetes.

Divers J, Register TC, Langefeld CD, Wagenknecht LE, Bowden DW, Carr JJ, Hightower RC, Xu J, Hruska KA, Freedman BI.

J Bone Miner Res. 2011 Jul;26(7):1554-60. doi: 10.1002/jbmr.389.

33.

RGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury.

Siedlecki AM, Jin X, Thomas W, Hruska KA, Muslin AJ.

Kidney Int. 2011 Aug;80(3):263-71. doi: 10.1038/ki.2011.63. Epub 2011 Mar 16.

34.

The roles of the skeleton and phosphorus in the CKD mineral bone disorder.

Hruska KA, Mathew S.

Adv Chronic Kidney Dis. 2011 Mar;18(2):98-104. doi: 10.1053/j.ackd.2011.01.001.

35.

A microRNA expression signature of osteoclastogenesis.

Sugatani T, Vacher J, Hruska KA.

Blood. 2011 Mar 31;117(13):3648-57. doi: 10.1182/blood-2010-10-311415. Epub 2011 Jan 27.

36.

Genomic signatures predict migration and spawning failure in wild Canadian salmon.

Miller KM, Li S, Kaukinen KH, Ginther N, Hammill E, Curtis JM, Patterson DA, Sierocinski T, Donnison L, Pavlidis P, Hinch SG, Hruska KA, Cooke SJ, English KK, Farrell AP.

Science. 2011 Jan 14;331(6014):214-7. doi: 10.1126/science.1196901.

37.

Influences of sex and activity level on physiological changes in individual adult sockeye salmon during rapid senescence.

Hruska KA, Hinch SG, Healey MC, Patterson DA, Larsson S, Farrell AP.

Physiol Biochem Zool. 2010 Jul-Aug;83(4):663-76. doi: 10.1086/652411.

PMID:
20482369
38.

Physiological condition differentially affects the behavior and survival of two populations of sockeye salmon during their freshwater spawning migration.

Donaldson MR, Hinch SG, Patterson DA, Farrell AP, Shrimpton JM, Miller-Saunders KM, Robichaud D, Hills J, Hruska KA, Hanson KC, English KK, Van Der Kraak G, Cooke SJ.

Physiol Biochem Zool. 2010 May-Jun;83(3):446-58. doi: 10.1086/649627.

PMID:
20367319
39.

Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).

Hruska KA, Choi ET, Memon I, Davis TK, Mathew S.

Pediatr Nephrol. 2010 Apr;25(4):769-78. doi: 10.1007/s00467-009-1337-0. Epub 2009 Nov 7. Review.

40.

Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study.

Freedman BI, Bowden DW, Ziegler JT, Langefeld CD, Lehtinen AB, Rudock ME, Lenchik L, Hruska KA, Register TC, Carr JJ.

J Bone Miner Res. 2009 Oct;24(10):1719-27. doi: 10.1359/jbmr.090501.

41.

CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas.

Kokubo T, Ishikawa N, Uchida H, Chasnoff SE, Xie X, Mathew S, Hruska KA, Choi ET.

J Am Soc Nephrol. 2009 Jun;20(6):1236-45. doi: 10.1681/ASN.2007121312. Epub 2009 May 7.

42.

The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature.

Hruska KA, Mathew S, Lund RJ, Memon I, Saab G.

Semin Nephrol. 2009 Mar;29(2):156-65. doi: 10.1016/j.semnephrol.2009.01.008. Review.

43.

Vascular smooth muscle cells in the pathogenesis of vascular calcification.

Hruska KA.

Circ Res. 2009 Mar 27;104(6):710-1. doi: 10.1161/CIRCRESAHA.109.195487. No abstract available.

PMID:
19325156
44.

Impaired micro-RNA pathways diminish osteoclast differentiation and function.

Sugatani T, Hruska KA.

J Biol Chem. 2009 Feb 13;284(7):4667-78. doi: 10.1074/jbc.M805777200. Epub 2008 Dec 5.

45.

Hyperphosphatemia of chronic kidney disease.

Hruska KA, Mathew S, Lund R, Qiu P, Pratt R.

Kidney Int. 2008 Jul;74(2):148-57. doi: 10.1038/ki.2008.130. Epub 2008 Apr 30. Review.

46.

Vitamin D receptor activators can protect against vascular calcification.

Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA.

J Am Soc Nephrol. 2008 Aug;19(8):1509-19. doi: 10.1681/ASN.2007080902. Epub 2008 Apr 30.

47.

The mechanism of phosphorus as a cardiovascular risk factor in CKD.

Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA.

J Am Soc Nephrol. 2008 Jun;19(6):1092-105. doi: 10.1681/ASN.2007070760. Epub 2008 Apr 16.

48.

Osteoporosis and cardiovascular disease: lessons from chronic kidney disease.

Hruska KA, Mathew S, Lund R.

Clin Cases Miner Bone Metab. 2008 Jan;5(1):35-9.

49.

Bone morphogenetic protein-7 delays podocyte injury due to high glucose.

De Petris L, Hruska KA, Chiechio S, Liapis H.

Nephrol Dial Transplant. 2007 Dec;22(12):3442-50. Epub 2007 Aug 8.

PMID:
17686813
50.

Renal osteodystrophy, phosphate homeostasis, and vascular calcification.

Hruska KA, Saab G, Mathew S, Lund R.

Semin Dial. 2007 Jul-Aug;20(4):309-15. Review.

PMID:
17635820

Supplemental Content

Loading ...
Support Center